UK calls for access to new AMD therapies

Article

Quantitative analysis of the impact of neovascular age-related macular degeneration (AMD) on the UK population has led a team of researchers to call for urgent, early access to the new class of drug therapies for the disease.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Related Content
The ZEISS Meditec logo in front of a graph showing a line up. Image credit: ©piter2121 – stock.adobe.com

Carl Zeiss Meditec AG announces completed acquisition of Dutch Ophthalmic Research Center

April 4th 2024
Article

Zeiss has secured regulatory approvals to acquire DORC and will shift focus to integration implementation

A detective looks through a magnifying glass at an eyeball. Image created with Canva AI.

Hemorrhagic unilateral retinopathy: No proven aetiology for rare condition

April 2nd 2024
Article

Multimodal imaging and a systemic work-up failed to identify any underlying disorder for the hemorrhages

Glasses with an overlay of digital data outputs on the surface. Image credit: ©Taiwo – stock.adobe.com

Exonate shares results from Phase Ib/IIa trial of EXN407 eye drops for DR and DME

March 27th 2024
Article

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

A scale, evenly balanced, with "risk" on one side and "benefit" on the other. ©Who is Danny – stock.adobe.com

COPHy 2024: Intraocular inflammation as a risk factor resulting from use of anti-complement agents for GA

March 15th 2024
Article

Good news for patients: use of anti-complement therapies have caused the growth rate of GA lesions to decrease

A doctor in a mask holds up a vial of medicine. Image credit: ©MYDAYcontent – stock.adobe.com

Kiora publishes results from Phase 1 study demonstrating safety, tolerability and efficacy of KIO-101

March 8th 2024
Article

Kiora also stated a Phase 2 trial of KIO-104 is expected to begin later this year

Image credit: ©vxnaghiyev – stock.adobe.com

The “fourth dimension” of home monitoring

March 4th 2024
Article

A longitudinal, AI-based approach to fluid quantification

© 2024 MJH Life Sciences

All rights reserved.